Zevra Therapeutics (NASDAQ:ZVRA) Stock Price Up 14.1% on Better-Than-Expected Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA)’s stock price was up 14.1% on Thursday after the company announced better than expected quarterly earnings. The company traded as high as $12.29 and last traded at $12.0150. 510,951 shares were traded during mid-day trading, a decline of 62% from the average session volume of 1,352,691 shares. The stock had previously closed at $10.53.

The company reported $0.25 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.14. The firm had revenue of $39.66 million for the quarter, compared to analysts’ expectations of $33.88 million. Zevra Therapeutics had a net margin of 101.58% and a return on equity of 51.49%.

Zevra Therapeutics News Summary

Here are the key news stories impacting Zevra Therapeutics this week:

• Positive Sentiment: Strong Q2 performance: Zevra reported $39.7 million in second-quarter revenue, up 53% year over year and above analyst expectations. MIPLYFFA generated $30.2 million, while earnings exceeded consensus estimates. The company also reported a strong cash position of $260.2 million, supporting commercialization and regulatory efforts. Zevra Reports Second Quarter 2026 Financial Results and Corporate Update
• Positive Sentiment: Analyst price-target increase: Citizens JMP raised its target for ZVRA from $25 to $28 and reiterated a “market outperform” rating. The revision reinforces the bullish view that MIPLYFFA’s commercial growth and Zevra’s rare-disease pipeline could support substantial long-term upside. Benzinga analyst price-target report
• Positive Sentiment: Regulatory and intellectual-property updates: Zevra said the European Medicines Agency’s CHMP reexamination process for MIPLYFFA is expected to produce an opinion in the fourth quarter. The product’s U.S. Orange Book listing has also been extended to 2041, potentially improving commercial exclusivity and the drug’s long-term revenue outlook. Zevra outlines CHMP reexamination timing
• Neutral Sentiment: Ownership signals are mixed: Several institutional investors increased positions, but others reduced holdings. Recent insider activity showed sales and no reported purchases, which may temper some investor enthusiasm but does not by itself establish a fundamental change.
• Negative Sentiment: Legal overhang: Pomerantz LLP announced an investigation into potential claims on behalf of Zevra investors. The announcement provided few substantive details, but securities investigations can create short-term uncertainty and volatility. Pomerantz investor alert

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. Weiss Ratings lowered Zevra Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research note on Friday, May 22nd. Guggenheim lowered their target price on shares of Zevra Therapeutics from $29.00 to $24.00 and set a “buy” rating for the company in a report on Monday, July 27th. Citigroup reiterated an “outperform” rating on shares of Zevra Therapeutics in a research note on Thursday. Wall Street Zen raised Zevra Therapeutics from a “hold” rating to a “buy” rating in a report on Sunday, July 12th. Finally, HC Wainwright reiterated a “buy” rating and set a $26.00 target price on shares of Zevra Therapeutics in a research report on Tuesday, June 23rd. Nine research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, Zevra Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.29.

Hedge Funds Weigh In On Zevra Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. AIGH Capital Management LLC purchased a new stake in Zevra Therapeutics in the first quarter worth about $11,184,000. Marshall Wace LLP acquired a new stake in Zevra Therapeutics in the third quarter valued at approximately $8,676,000. Rubric Capital Management LP grew its stake in Zevra Therapeutics by 60.8% during the 2nd quarter. Rubric Capital Management LP now owns 1,958,318 shares of the company’s stock worth $17,253,000 after buying an additional 740,584 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its holdings in shares of Zevra Therapeutics by 15.2% during the second quarter. Adage Capital Partners GP L.L.C. now owns 4,168,000 shares of the company’s stock valued at $36,720,000 after acquiring an additional 550,000 shares in the last quarter. Finally, Nantahala Capital Management LLC increased its stake in Zevra Therapeutics by 34.0% during the 3rd quarter. Nantahala Capital Management LLC now owns 1,971,936 shares of the company’s stock valued at $18,753,000 after purchasing an additional 500,000 shares in the last quarter. 35.03% of the stock is currently owned by institutional investors.

Zevra Therapeutics Trading Up 13.4%

The firm has a 50-day moving average of $12.31 and a 200-day moving average of $10.55. The stock has a market capitalization of $705.60 million, a price-to-earnings ratio of 5.97 and a beta of 0.91.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.